Rate Notice: 5.9% general rate increase Jan 1, 2026 — Learn More
    Teikoku Pharma USA Inc logo displaying a stylized blue and white emblem with the company name

    Teikoku Pharma Usa Inc.

    Teikoku Pharma USA Inc. is a California-based specialty pharmaceutical company focused on innovative drug delivery technologies for pain management, CNS disorders, and dermatology.

    Company Overview

    Teikoku Pharma USA Inc. (TPU), founded in 1997, is a privately held subsidiary of Teikoku Seiyaku of Japan. The company specializes in developing and manufacturing pharmaceutical products, particularly transdermal patches, for the U.S. and global markets. Its core therapeutic areas include pain management, central nervous system (CNS) disorders, and dermatology.

    Key Metrics

    50

    Import Shipments

    1

    Distribution Centers

    50.0M

    Annual Revenue

    1997

    Founded

    Company Profile

    Key Milestones

    Important company milestones and achievements.

    Markets Served

    Geographic markets and customer segments served.

    Ownership Structure

    Corporate ownership and organizational structure.

    Sales Channels

    Distribution networks and sales approaches.

    Recent Developments

    Teikoku Pharma USA is likely advancing its R&D pipeline, expanding partnerships, and exploring new drug delivery technologies in response to evolving pharmaceutical industry trends.

    Strategic Expansion

    Expansion of R&D efforts in transdermal and topical drug delivery systems

    Market Expansion

    Strategic efforts to expand market presence and reach new customer segments.

    Technology Adoption

    Implementation of advanced technologies to improve service delivery and customer experience.

    Business Information

    Teikoku Pharma USA Inc. leverages proprietary drug delivery technologies to develop innovative pharmaceutical products, with a strong focus on transdermal patches. Its flagship product, Lidoderm® (Lidocaine 5% Patch), is widely used for the treatment of postherpetic neuralgia and is distributed in the U.S. and internationally. The company’s R&D and manufacturing teams are based in California, supporting a robust pipeline in pain management, CNS, and oncology. As a subsidiary of Teikoku Seiyaku, TPU benefits from a global network and a legacy of pharmaceutical innovation.

    Headquarters

    San Jose, California

    Founded

    1997

    Stock Symbol

    Private company